TipRanks
Zenas BioPharma, Inc. (ZBIO)
NASDAQ:ZBIO
US Market
ZBIO
Zenas BioPharma, Inc.
RESEARCH TOOLSreports
Want to see ZBIO full AI Analyst Report?

Zenas BioPharma, Inc. (ZBIO) Ratios

316 Followers

Zenas BioPharma, Inc. Ratios

ZBIO's free cash flow for Q2 2026 was $1.00. For the 2026 fiscal year, ZBIO's free cash flow was decreased by $ and operating cash flow was $-101.04. See a summary of the company’s cash flow.
Ratios
TTM
Dec 25Dec 24Dec 23Dec 22
Liquidity Ratios
Current Ratio
 9.93 5.61 6.21 2.57
Quick Ratio
 9.93 5.61 6.21 2.57
Cash Ratio
 2.99 1.77 5.58 2.44
Solvency Ratio
 -1.07 -2.67 -2.73 -0.13
Operating Cash Flow Ratio
 -3.43 -2.75 -2.09 -1.31
Short-Term Operating Cash Flow Coverage
 -274.57 -154.56 0.00 0.00
Net Current Asset Value
$ 199.20M$ 209.68M$ 298.41M$ -234.10M
Leverage Ratios
Debt-to-Assets Ratio
 0.56 0.21 <0.01 0.31
Debt-to-Equity Ratio
 1.58 0.33 <0.01 -0.09
Debt-to-Capital Ratio
 0.61 0.25 <0.01 -0.10
Long-Term Debt-to-Capital Ratio
 0.61 0.25 0.00 -0.10
Financial Leverage Ratio
 2.84 1.58 1.18 -0.30
Debt Service Coverage Ratio
 -25.77 -43.87 0.00 0.00
Interest Coverage Ratio
 -28.09 -28.85 0.00 0.00
Debt to Market Cap
 0.23 0.05 0.00 0.03
Interest Debt Per Share
 6.44 1.95 0.02 0.55
Net Debt to EBITDA
 -0.42 0.08 2.04 1.32
Profitability Margins
Gross Profit Margin
-5972.60%100.00%-2682.78%100.00%
EBIT Margin
-45731.10%-3704.89%-3131.18%-54.29%
EBITDA Margin
-45728.00%-3704.33%-3128.44%-54.07%
Operating Profit Margin
-47557.30%-2113.85%-3277.76%-74.29%
Pretax Profit Margin
-48416.40%-3778.16%-3131.18%-73.65%
Net Profit Margin
-48438.40%-3777.37%-3139.76%-74.25%
Continuous Operations Profit Margin
-48438.40%-3777.37%-3139.76%-74.25%
Net Income Per EBT
100.05%99.98%100.27%100.82%
EBT Per EBIT
101.81%178.73%95.53%99.13%
Return on Assets (ROA)
-69.03%-98.46%-42.43%-54.45%
Return on Equity (ROE)
-189.68%-156.00%-50.24%16.45%
Return on Capital Employed (ROCE)
-74.79%-65.85%-52.41%-82.69%
Return on Invested Capital (ROIC)
-74.69%-65.61%-52.28%-81.68%
Return on Tangible Assets
-69.03%-98.46%-42.43%-54.45%
Earnings Yield
-28.46%-23.26%-45.87%-5.39%
Efficiency Ratios
Receivables Turnover
 1.25 0.00 0.00 0.00
Payables Turnover
 8.00 0.00 8.12 0.00
Inventory Turnover
 0.00 0.00 0.00 0.00
Fixed Asset Turnover
 1.18 7.20 4.21 49.31
Asset Turnover
 <0.01 0.03 0.01 0.73
Working Capital Turnover Ratio
 <0.01 0.03 0.03 1.27
Cash Conversion Cycle
 246.39 0.00 -44.95 0.00
Days of Sales Outstanding
 292.00 0.00 0.00 0.00
Days of Inventory Outstanding
 0.00 0.00 0.00 0.00
Days of Payables Outstanding
 45.61 0.00 44.95 0.00
Operating Cycle
 292.00 0.00 0.00 0.00
Cash Flow Ratios
Operating Cash Flow Per Share
 -3.58 -3.85 -2.86 -0.80
Free Cash Flow Per Share
 -3.58 -3.85 -2.87 -0.80
CapEx Per Share
 <0.01 <0.01 <0.01 <0.01
Free Cash Flow to Operating Cash Flow
 1.00 1.00 1.00 1.00
Dividend Paid and CapEx Coverage Ratio
 -112.99K -9.57K -913.54 -1.80K
Capital Expenditure Coverage Ratio
 -112.99K -9.57K -913.54 -1.80K
Operating Cash Flow Coverage Ratio
 -0.58 -2.16 -119.32 -1.45
Operating Cash Flow to Sales Ratio
 -225.97 -17.23 -23.93 -0.61
Free Cash Flow Yield
-13.27%-10.61%-35.01%-4.44%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 -2.80 -4.30 -2.18 -18.55
Price-to-Sales (P/S) Ratio
 1.70K 162.41 68.44 13.77
Price-to-Book (P/B) Ratio
 6.89 6.71 1.10 -3.05
Price-to-Free Cash Flow (P/FCF) Ratio
 -7.53 -9.42 -2.86 -22.54
Price-to-Operating Cash Flow Ratio
 -7.53 -9.42 -2.86 -22.55
Price-to-Earnings Growth (PEG) Ratio
 0.03 -0.03 >-0.01 0.27
Price-to-Fair Value
 6.89 6.71 1.10 -3.05
Enterprise Value Multiple
 -4.15 -4.30 -0.15 -24.15
Enterprise Value
 1.90B 1.59B 23.48M 652.81M
EV to EBITDA
 -4.15 -4.30 -0.15 -24.15
EV to Sales
 1.90K 159.35 4.70 13.06
EV to Free Cash Flow
 -8.39 -9.25 -0.20 -21.37
EV to Operating Cash Flow
 -8.39 -9.25 -0.20 -21.38
Tangible Book Value Per Share
 3.92 5.41 7.48 -5.89
Shareholders’ Equity Per Share
 3.92 5.41 7.48 -5.89
Tax and Other Ratios
Effective Tax Rate
 >-0.01 <0.01 >-0.01 >-0.01
Revenue Per Share
 0.02 0.22 0.12 1.30
Net Income Per Share
 -7.67 -8.44 -3.76 -0.97
Tax Burden
 1.00 1.00 1.00 1.01
Interest Burden
 1.06 1.02 1.00 1.36
Research & Development to Revenue
 380.15 16.81 27.83 1.20
SG&A to Revenue
 61.42 5.33 5.95 0.34
Stock-Based Compensation to Revenue
 32.73 2.63 2.16 0.07
Income Quality
 0.47 0.46 0.76 0.82
Currency in USD